Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo’s XBB-Tailored Jab
The Japanese government on November 28 granted approval to Meiji Seika Pharma’s COVID-19 vaccine Kostaive and an updated version of Daiichi Sankyo’s jab Daichirona targeting the XBB Omicron subvariant of the novel coronavirus. Both are mRNA vaccines. Previously known as…
To read the full story
Related Article
- Meiji’s Kostaive Booster Dose Non-Inferior to Pfizer COVID Jab: PIII Data
December 25, 2023
- Meiji Set to Start Supplying COVID Jab in Japan Next Fall-Winter
November 29, 2023
- Debut of Japan-Made COVID-19 Jab Is Momentous: Daiichi Sankyo President
November 29, 2023
- Meiji’s mRNA Vaccine, Pfizer’s RSV Vaccine Now in Line for Approval
November 28, 2023
REGULATORY
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
- HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
- MHLW Orders Label Revisions for PPIs, Checkpoint Inhibitors
July 15, 2026
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…